A leading provider of
innovative DNA Screening solutions
MLL Breakapart LPH013
Rearrangement of the MLL gene can be detected in the leukaemia cells of approximately 85% of infants with B-ALL. Translocations involving the MLL (11q23) gene are generally associated with an increased risk of treatment failure. The most frequently observed of these translocations is the t(4;11) translocation involving the MLL gene and the AF4 gene on chromosome 4. A poor outcome for infants with ALL is strongly associated with the presence of this rearrangement in particular.
MLL Breakapart Probe
Cat. No. LPH 013-S (5 tests)
Cat. No. LPH 013 (10 tests)
This webpage could contain information on product details or information not valid in your country or region. Please be aware that we do not take any responsibility for accessing such information, which may not comply with any legal process, regulation, registration or usage in the country of your origin. If you are a resident of a country other than those to which this site is directed, contact your local Cytocell distributor to obtain the appropriate product information for your country of residence.
Developed &produced in the UK